ascopubs.org

Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?

Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? The following represents disclosure information provided by the author of ...
Cure Today

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
ascopubs.org

Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). † 2 pts experienced TEAEs ...

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...